You just read:

SYN-004 (Ribaxamase) Receives Breakthrough Therapy Designation from U.S. Food and Drug Administration for Prevention of Clostridium difficile Infection

News provided by

Synthetic Biologics, Inc.

May 11, 2017, 07:00 ET